Corn PG, Heath EI, Zurita A, et al. - Researchers examined how carboplatin addition to cabazitaxel would impact the outcomes of men with metastatic castration-resistant prostate cancer. At two centers, a phase 1–2, open-label, randomized study in men with progressive metastatic castration-resistant prostate cancer was performed. In phase 1, they administered intravenous cabazitaxel 20–25 mg/m ² and intravenous carboplatin area under the curve (AUC) 3–4 mg/mL per min every 21 days to the patients. They defined the maximum tolerated dose as the highest dose cohort studied in which one of six or fewer patients experienced dose-limiting toxicity. In phase 2, they randomly assigned patients (1:1) to intravenous cabazitaxel 25 mg/m ² with or without intravenous carboplatin AUC 4 mg/mL per min. Outcomes revealed improved clinical efficacy in correlation with the administration of carboplatin added to cabazitaxel compared with cabazitaxel alone for men with metastatic castration-resistant prostate cancer. The combination led to an improvement in the median progression-free survival from 4·5 months to 7·3 months. Despite a more common occurrence of adverse events with the combination, the treatment was safe and generally well-tolerated. Data support taxane–platinum combinations as clinically beneficial in advanced prostate cancer.